SLC5A2 and hydrops fetalis: Landmark trials evaluating the efficacy and safety of the use of SGLT2 inhibitors in HF, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER, showed similar positive outcomes, although the studied populations were limited to patients with chronic HF, excluding those with recent ACS (6–9).